Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

347
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
347
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

443
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
443
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypothesis-generating analysis of mutational signatures in childhood B-cell acute lymphoblastic leukemia in relation to socio-demographic, genetic, and environmental factors: A report from the Children's Oncology Group.

medRxiv : the preprint server for health sciences·2025
Same author

Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci.

Nature communications·2025
Same author

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome.

Blood·2025
Same author

Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.

Blood advances·2025
Same author

Environmental health disparities in pediatric cancer: a report from the Fourth Symposium on Childhood Cancer Health Disparities.

Pediatric hematology and oncology·2025
Same author

The impact of Indigenous American-like ancestry on risk of acute lymphoblastic leukemia in Hispanic/Latino children.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Sep 12, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.3K

Toward Equitable Risk Classification for All Patients with T-ALL.

Adam J de Smith1

  • 1Center for Genetic Epidemiology, University of Southern California Keck School of Medicine, Los Angeles, California.

Blood Cancer Discovery
|August 8, 2025
PubMed
Summary

Genetic ancestry impacts T-cell acute lymphoblastic leukemia (T-ALL) subtypes and survival. Genomic alterations like NOTCH1 mutations have varying prognostic value across different ancestries, crucial for risk stratification.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Related Experiment Videos

Last Updated: Sep 12, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease.
  • Understanding factors influencing T-ALL outcomes is critical for effective treatment.

Purpose of the Study:

  • To investigate the influence of genetic ancestry on molecular subtypes, genomic alterations, and survival in T-ALL patients.
  • To assess the prognostic utility of specific genomic alterations across diverse ancestral groups.

Main Methods:

  • Analysis of a diverse patient cohort with T-cell acute lymphoblastic leukemia.
  • Examination of molecular subtypes and genomic alterations.
  • Correlation of genetic ancestry with survival outcomes and alteration prognostic value.

Main Results:

  • Genetic ancestry significantly impacts molecular subtypes and survival outcomes in T-ALL.
  • The prognostic utility of genomic alterations differs across ancestral groups.
  • NOTCH1 mutations lacked prognostic utility in patients of predominantly African ancestry.

Conclusions:

  • Genetic ancestry is a critical factor in T-ALL risk stratification.
  • Genomic alterations must be interpreted in the context of patient ancestry.
  • Future T-ALL research and clinical practice should incorporate genetic ancestry.